{"product_id":"c4a-antibody-complement-c4a-bha17109989","title":"C4A Antibody \/ Complement C4A","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eC4A Antibody \/ Complement C4A is a research-use antibody directed against \u003cstrong\u003eC4A\u003c\/strong\u003e. It is supplied for use in common immunoassay contexts such as WB (RUO).\u003c\/p\u003e\n\n\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e C4A.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eDescription (provided):\u003c\/strong\u003e This gene encodes the acidic form of complement factor 4, part of the classical activation pathway.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eAntibody type:\u003c\/strong\u003e Rabbit, clone AFHB-3, Rabbit IgG.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Purified; Affinity purified.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e tested: Human.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eImmunogen (if provided):\u003c\/strong\u003e A synthetic peptide specific to human C4A \/ Complement C4A was used as the immunogen for the C4A antibody..\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe information above helps you match the antibody format to your assay context, interpret species-dependent differences, and anticipate how epitope context (isoforms, PTMs, or conformational state) may influence signal.\u003c\/p\u003e\n\n\u003ch2\u003eBiological background\u003c\/h2\u003e\n\u003cp\u003eThis gene encodes the acidic form of complement factor 4, part of the classical activation pathway. The protein is expressed as a single chain precursor which is proteolytically cleaved into a trimer of alpha, beta, and gamma chains prior to secretion. The trimer provides a surface for interaction between the antigen-antibody complex and other complement components. The alpha chain is cleaved to release C4 anaphylatoxin, an antimicrobial peptide and a mediator of local inflammation. Deficiency of this protein is associated with systemic lupus erythematosus and type I diabetes mellitus. [RefSeq]\u003c\/p\u003e\n\u003cp\u003eFor curated annotations (gene\/protein naming, domains, isoforms, and pathway links) for C4A, consult primary databases such as UniProt, NCBI Gene, and Ensembl.\u003c\/p\u003e\n\n\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003eContext-dependent expression studies: researchers often examine C4A abundance and localization across perturbations (genetic, pharmacologic, or environmental) to connect phenotype to molecular changes.\u003c\/li\u003e  \u003cli\u003eReagent reproducibility: there is growing emphasis on antibody specificity checks using orthogonal approaches (e.g., genetic perturbation or independent antibodies) and transparent reporting of clone\/lot information.\u003c\/li\u003e  \u003cli\u003eMulti-modal datasets: antibody-based readouts are increasingly combined with transcriptomics and imaging to relate protein-level measurements to cell-state transitions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon research applications\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003eWestern blotting (immunoblot) for relative detection of target protein abundance and apparent molecular weight.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhen comparing conditions, interpret changes in signal in the context of sample composition, expected localization, and any known isoform complexity for the target.\u003c\/p\u003e\n\n\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \n\u003cli\u003e\n\u003cstrong\u003eIsoforms and PTMs:\u003c\/strong\u003e alternative splicing or post-translational modifications can change epitope accessibility and apparent molecular weight; interpret bands\/signals accordingly.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eCross-reactivity and matrix effects:\u003c\/strong\u003e background binding can vary by sample type, species, and blocking\/detection chemistries; include appropriate negative controls.\u003c\/li\u003e  \u003cli\u003e\n\u003cstrong\u003eControl concepts:\u003c\/strong\u003e where feasible, use genetic perturbation (KO\/KD\/overexpression), orthogonal assays, or independent antibodies to support specificity claims.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eAntibody considerations:\u003c\/strong\u003e Polyclonal reagents may recognize multiple epitopes and can increase sensitivity but may show broader binding profiles, while monoclonal clones provide a single-epitope readout that can improve consistency across experiments. If a conjugate is listed, the antibody supports more direct detection workflows; otherwise, it is typically used with a compatible secondary antibody.\u003c\/p\u003e\n\n\u003c!-- Sources (internal):\n- UniProtKB entry for C4A (UniProt): https:\/\/www.uniprot.org\/uniprotkb\/P0C0L4\n- NCBI Gene search for C4A (NCBI): https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=C4A\n- Ensembl gene search for C4A (Ensembl): https:\/\/www.ensembl.org\/Multi\/Search\/Results?q=C4A\n- Antibody validation “5 pillars” (Nature Methods, 2016): https:\/\/www.nature.com\/articles\/nmeth.3995\n- NIH replication \u0026 reproducibility resources (NIH): https:\/\/www.nih.gov\/replicationandreproducibility\n- Human Protein Atlas search for C4A (HPA): https:\/\/www.proteinatlas.org\/search\/C4A\n--\u003e","brand":"NSJ Bioreagents","offers":[{"title":"Antibody in PBS with 0.02% sodium azide, 50% glycerol and 0.4-0.5mg\/ml BSA \/ 100 ul","offer_id":53044503478637,"sku":"RQ5301","price":449.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_0a47b555-7295-45c4-a03e-4b4886cf69bd.jpg?v=1771939052","url":"https:\/\/www.ebiohippo.com\/products\/c4a-antibody-complement-c4a-bha17109989","provider":"BioHippo","version":"1.0","type":"link"}